Brinzolamide

CAS No. 138890-62-7

Brinzolamide( AL 4862 | Azopt )

Catalog No. M11614 CAS No. 138890-62-7

Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 31 In Stock
10MG 45 In Stock
25MG 86 In Stock
50MG 133 In Stock
100MG 194 In Stock
200MG 243 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Brinzolamide
  • Note
    Research use only, not for human use.
  • Brief Description
    Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor.
  • Description
    Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase inhibitor. Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure. Brinzolamide is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. (In Vivo):Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.
  • In Vitro
    ——
  • In Vivo
    Brinzolamide (7.5 mg or 12 mg) implanted in a silicone matrix is extremely well tolerated and provides sustained release of brinzolamide and significant reduction in intraocular pressure (IOP) for up to 28 days with no adverse effects or signs of toxicity in normotensive NZW rabbits.The pharmacokinetic parameters of Brinzolamide in rabbits.Animal Model:Rabbits Dosage:7.5 mg, 12 mg Administration:Brinzolamide silicone matrix implant placed in the episcleral space Result:Resulted in a significant IOP reduction of 4.6 mmHg on days 10-28, with concentrations of 12 mg.
  • Synonyms
    AL 4862 | Azopt
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Carbonic Anhydrase
  • Recptor
    Carbonic anhydrase II
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    138890-62-7
  • Formula Weight
    383.51
  • Molecular Formula
    C12H21N3O5S3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 77 mg/mL (200.77 mM)
  • SMILES
    CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Stams T, et al. Protein Sci. 1998 Mar;7(3):556-63.
molnova catalog
related products
  • Enpp/Carbonic anhydr...

    Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent inhibitor of Enpp and carbonic anhydrase, exhibiting IC50s of 1.36, 1.35, 3.00, 0.88, and 1.02 μM for NPP1, NPP2, NPP3, CA-II, and CA-IX respectively.

  • hCAIX-IN-5

    hCAIX-IN-5 was a selective hCAIX inhibitor, inhibiting hCAI, hCAII, hCAIV, and hCAIX with Ki values of >10000, >10000, 130.7, and 829.1 nM, respectively.

  • Dorzolamide hydrochl...

    Dorzolamide Hcl(L671152 Hcl; MK507 Hcl) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor.